bit.bio partners with myriamed to add iPSC-derived cardiomyocytes to drug discovery portfolio

By Public Technologies
  • bit.bio entered an exclusive partnership with Germany’s myriamed to add human iPSC-derived cardiomyocytes to its drug discovery portfolio.
  • The deal expands its human cell offering to three key drug-safety organ systems: heart, liver, central nervous system.
  • bit.bio will exclusively offer cryopreserved ventricular, atrial cardiomyocytes, including a dilated cardiomyopathy model, for ready-to-plate use.
  • The cardiomyocyte suite will also be available through its CRISPR screening services, extending use into phenotypic screening and safety testing.
  • Partnership announced on Sept. 23, 2026, positioning the companies for broader adoption of human-relevant models in preclinical testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bit.bio Ltd. published the original content used to generate this news brief on September 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.